



CARBON REDUCTION PLAN

Supplier name: G.L. Pharma UK Limited

Publication date : May 2025

Commitment to achieving Net Zero

GL Pharma UK Limited is committed to achieving Net Zero emissions by 2050.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2023	
Additional Details relating to the Baseline Emissions calculations.	
The baseline exercise was carried out for the first time for the year 2023 for the bidding entity – GL Pharma UK Limited. The carbon footprint adopts the scope of the PPN 06/21 regulations and standards, and all relevant Scope 3 categories have been included	
Baseline year emissions:	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	0
Scope 2	1.10 (Purchased electricity & Heating)
Scope 3 (Included Sources)	41.13 Business travel (5.50) Employee commuting (5.60) Upstream transportation/distribution (26.20) Product waste/disposal (0.23) Downstream transportation/distribution (3.60)
Total Emissions	42.23

Current Emissions Reporting

Reporting Year: 2024	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	0
Scope 2	1.10 (Purchased electricity & Heating)
Scope 3 (Included Sources)	127.23 Business travel (5.50) Employee commuting (5.60) Upstream transportation/distribution (109.20) Product waste/disposal (0.23) Downstream transportation/distribution (6.70)
Total Emissions	128.33

Emissions reduction targets

GL Pharma UK Limited is committed to achieving Net Zero by 2050

In order to continue our progress to achieving Net Zero, we have adopted the following carbon reduction targets. It is worth noting that we are a SME business which only commenced trading in 2022 and have plans to grow our business in the UK, we intend to transition to intensity based targets in the future. For 2025 we have established the following absolute reduction targets:

Business Travel

Emissions in 2024: 5.5 tonnes

- Whilst this remains constant from 2023 to 2024, our aim is to reduce this by 10% (0.55 tonnes) to a total of 4.95 tonnes by the end of 2025. This will be achieved by reducing air travel whenever possible (to both our Head office and overseas meetings) and where possible travel to UK customer meetings by train rather than by car.

Employee Commuting

Emissions in 2024: 5.6 tonnes

- As a small business with a low number of employees, the scope to reduce this further is limited. Currently, G.L. Pharma UK Ltd support hybrid working which helps to reduce emissions related to commuting. Additionally, G.L. Pharma UK Ltd also offers employees a Cycle to Work Scheme which has been adopted by 75% of the workforce.


Upstream Transportation/Distribution

Emissions in 2024: 109.2 tonnes

- In the long term our aim is to reduce this amount (% reduction to be determined) This will be achieved by delivery rationalisation and ensuring we ship full HGV loads. The emission figure of 109.2 tonnes is expected to increase as our business continues to grow. However, we are planning to reduce our emissions per pack in parallel.

Building upon the outlined targets for emissions reduction, we project that GL Pharma carbon emissions will increase in the short-term whilst we establish our UK business but then gradually reduce as we implement our carbon reduction strategy across our UK footprint.

Progress against these targets can be seen in the graph below:



Carbon Reduction Projects

Completed Carbon Reduction Initiatives

The following environmental management measures and projects have been completed or implemented since the 2023 baseline.

Limiting the impact of travel

- We encourage the use of rail travel among our employees rather than air or road travel.
- When colleagues need to visit customers, we promote car sharing rather than travelling independently.
- Overseas travel to meetings and to our Austrian manufacturing facility are for necessary business reasons.
- We have implemented hybrid working with only 3 days a week in the office for 50% of the workforce 2 days a week for 25% of the workforce and 1 day a week for 25% of the workforce

Employee Commuting

- A cycle-to-work scheme has been introduced to incentivise employees to choose cycling as a means of transportation. This decreases the driving emissions to the office. Over 50% of workforce currently cycles to work.

Future Carbon Reduction initiatives

Downstream Transportation vehicle Emissions

During 2024, G.L. Pharma UK Ltd transitioned the provision of downstream transportation to a new provider. Based on data provided, we expect to see a reduction in downstream transport emissions from 6.5gm per pack to 6.1gm per pack (a reduction of >6%).

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>

³<https://ghgprotocol.org/standards/scope-3-standard>

Signed on behalf of the Supplier:


.....

Matt Homent
Managing Director

Date: ...4 June 2025.....